---

A study at BRIMS hospital for comparing the tolerability of Cilnidipine and Amlodipine in the treatment of hypertension

---

Original Article

Author Details : Preeti M Dharpur*, Kavitha V.C

Volume : 6, Issue : 1, Year : 2019

Article Page : 11-13

https://doi.org/10.18231/2393-9087.2019.0003

Suggest article by email

Get Permission

---

Abstract

Introduction: Few of the antihypertensive medicine have been withdrawn owing ADRs. Some are serious enough leading to hospitalization or withdrawal of treatment.
Objective: To study the tolerability of Cilnidipine and Amlodipine in patients of hypertensive.
Materials and Methods: This study was a collaboration between department of Pharmacology and Medicine of Bidar Institute of Medical Sciences (BRIMS), Bidar. Duration of study was for 9 months from May 2018- January 2019. 100 newly diagnosed mild and moderate hypertensive patients of either sex aged between 18-60yrs were included. ADR were noted and compared using parametric test. Significance was defined as P < 0>
Result: The patients mean age receiving Cilnidipine was 42.98 ± 8.35 and Amlodipine was 44.48 ± 9.03. On comparison of ADRs between Cilnidipine and Amlodipine it is clear that Amlodipine has more ADRs than Cilnidipine. The Comparison of pedal edema between both the groups show a Statistical Significance with p= 0.0003.
Conclusion: It can be concluded from our study that Cilnidipine seems to be better than Amlodipine in the management of the hypertensive patients.

Keywords: ADRs, Cilnidipine, Amlodipine, Antihypertensive drugs.

How to cite : Dharpur P M, V.c K, A study at BRIMS hospital for comparing the tolerability of Cilnidipine and Amlodipine in the treatment of hypertension. Indian J Pharm Pharmacol 2019;6(1):11-13

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.